Active, Not Recruiting A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma NCT05732805 Conditions Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Melanoma (Skin), +16 more Locations Healthcare Institution "Bobruisk Interdistrict Oncological Dispensary" — Babruysk, Belarus Healthcare Institution "Brest Regional Oncological Dispensary" — Brest, Belarus Health care institution "Grodno University Clinic" — Grodno, Belarus Health Institution "Gomel Regional Clinical Oncology Center" — Homyel, Belarus View all 63 locations View more locations Show fewer locations Loading locations... View Trial Details
